ipilimumab/nivolumab
1 product
5 abstracts
Abstract
Examination of irAE and treatment discontinuation irAE in patients with RCC with T effector phenotype.Org: Vindhya Data Science,
Abstract
Use of immunotherapy with check point inhibitors in soft tissue sarcoma: Analysis from single institution.Org: University of Louisville, James Graham Brown Cancer Center,
Abstract
Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma.Org: Memorial Sloan Kettering Cancer Center, Weill Medical College,
Abstract
Five-year survival outcomes in patients with melanoma with complete response to immunotherapy who discontinue therapy.Org: University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Abramson Cancer Center, University of Pennsylvania,